<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00415766</url>
  </required_header>
  <id_info>
    <org_study_id>ovitrelle vs pregnyl</org_study_id>
    <nct_id>NCT00415766</nct_id>
  </id_info>
  <brief_title>Comparison Between Recombinant Versus Urinary hCG for Ovulation Induction in High Responders</brief_title>
  <official_title>Recombinant hCG (Ovitrelle) Vesrus Urinary hCG (Pregnyl) for Triggering Final Oocyte Maturation in High Responders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eugonia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eugonia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the clinical outcomes of recombinant human chorionic
      gonadotrophin (rHCG) and urinary HCG (uHCG) in patients undergoing IVF cycles.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Urinary human chorionic gonadotrophin (u-hCG) has been widely used to induce final oocyte
      maturation and to trigger ovulation in assisted conception. Recombinant technology has
      allowed the production of r-hCG inj which all urinary contaminants are absent. Hence, this
      would allow the safe subcutaneous administration of a compound with less batch-to-batch
      variation. This study will investigate the effectiveness of the recombinant hCG compared to
      the currently used urinary hCG.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of mature oocytes</measure>
    <time_frame>Day of oocyte retrieval (Day 0)</time_frame>
    <description>Percentage MII/COCs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive test per embryo transfer</measure>
    <time_frame>15 days post oocyte retrieval</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy per embryo transfer</measure>
    <time_frame>7 weeks of gestation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ongoing pregnancy per embryo transfer</measure>
    <time_frame>12 weeks of gestation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of serum hCG on day of oocyte retrieval</measure>
    <time_frame>Day of oocyte retrieval</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of oocytes (COC) retrieved</measure>
    <time_frame>Day of oocyte retrieval</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of mature oocytes (MII)</measure>
    <time_frame>Day of oocyte retrieval</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oocyte retrieval rate</measure>
    <time_frame>Day of oocyte retrieval (Day 0)</time_frame>
    <description>Number of oocytes retrieved/number of follicles on the day of triggering final oocyte maturation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe early OHSS</measure>
    <time_frame>up to Day 5 post oocyte retrieval</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>rHCG 250 ug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Injection of 250 ug Ovitrelle to trigger final oocyte maturation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>uHCG 5000 IU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Injection of 5000 IU Pregnyl to trigger final oocyte maturation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>uHCG 7500 IU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Injection of 7500 IU Pregnyl to trigger final oocyte maturation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rHCG 250ug</intervention_name>
    <description>Injection of 250 ug Ovitrelle to trigger final oocyte maturation</description>
    <arm_group_label>rHCG 250 ug</arm_group_label>
    <other_name>Ovitrelle</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>uHCG 5000 IU</intervention_name>
    <description>Injection of 5000 IU Pregnyl to trigger final oocyte maturation</description>
    <arm_group_label>uHCG 5000 IU</arm_group_label>
    <other_name>Pregnyl 5000 IU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>uHCG 7500 IU</intervention_name>
    <description>Injection of 7500 IU Pregnyl to trigger final oocyte maturation</description>
    <arm_group_label>uHCG 7500 IU</arm_group_label>
    <other_name>Pregnyl 7500 IU</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 14 follicles &gt;11mm on the day of triggering final oocyte maturation

          -  Pretreated with GnRH antagonist protocol

        Exclusion Criteria:

          -  Poor responders

          -  Women with 25 or more follicles on the day of trigger
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tryfon Lainas, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eugonia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eugonia</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <reference>
    <citation>Revelli A, Poso F, Gennarelli G, Moffa F, Grassi G, Massobrio M. Recombinant versus highly-purified, urinary follicle-stimulating hormone (r-FSH vs. HP-uFSH) in ovulation induction: a prospective, randomized study with cost-minimization analysis. Reprod Biol Endocrinol. 2006 Jul 18;4:38.</citation>
    <PMID>16848893</PMID>
  </reference>
  <reference>
    <citation>Al-Inany HG, Aboulghar M, Mansour R, Proctor M. Recombinant versus urinary human chorionic gonadotrophin for ovulation induction in assisted conception. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD003719. Review. Update in: Cochrane Database Syst Rev. 2011;(4):CD003719.</citation>
    <PMID>15846677</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2006</study_first_submitted>
  <study_first_submitted_qc>December 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2006</study_first_posted>
  <last_update_submitted>January 18, 2016</last_update_submitted>
  <last_update_submitted_qc>January 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recombinant hCG</keyword>
  <keyword>urinary hCG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chorionic Gonadotropin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

